NIH R01 · 2025
Immunosuppressive mechanisms of intratumoral regulatory T cells
PROJECT SUMMARY Immune-based cancer therapies have revolutionized the treatment of cancer. However, immunosuppression within tumors remains a major obstacle for their success. Regulatory T cells (Tregs), an immunosuppressive subset of CD4+ T cells, are heavily recruited to most tumors where they may suppress antitumor immune responses directly within tumors. Tregs may also impose immunosuppression directly in the lymph nodes draining the tumor (tdLN), limiting T cell priming events that generate robust and potent antitumor T cells. Where Tregs function, in the tumor, tdLN, or both, is of critical importance for Treg-targeting cancer therapies because disrupting Tregs systemically will be…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.